However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

As of the end of 2024, the dermatology prescription portfolio of CMS Skinhealth has comprehensively covered dermatology diseases, such as vitiligo, psoriasis, atopic dermatitis, phlebitis ...

Medtronic’s VenaSeal Spectrum postmarket clinical trial program is highlighting the need for further patient-centric ...

Click to Subscribe to Get Our Free HollywoodLife Daily Newsletter to get the hottest celeb news. Articles Trending Now ...